Overall, we provide proof-of-principle that cDC1 reprogramming in situ represents a tumor origin-agnostic, off-the-shelf yet personalized immunotherapy modality able to orchestrate systemic and durable antitumor immunity. This evidence concerns the gene MPPE1 and neoplasm.